JPMORGAN CHASE & CO - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 167 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2014. The put-call ratio across all filers is 2.06 and the average weighting 0.1%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q4 2018$1,0007,434
+292.7%
0.00%
Q3 2018$0
-100.0%
1,893
+89.3%
0.00%
Q2 2018$1,000
-100.0%
1,000
-99.9%
0.00%
Q1 2018$2,309,000
+2750.6%
991,184
+3392.4%
0.00%
Q4 2017$81,000
-95.9%
28,381
-94.9%
0.00%
Q1 2017$1,994,000
-10.9%
552,166
-12.6%
0.00%
-100.0%
Q4 2016$2,237,000
-8.2%
631,900
+4.7%
0.00%0.0%
Q3 2016$2,438,000
-12.2%
603,700
-4.6%
0.00%0.0%
Q2 2016$2,776,000
+6.4%
632,520
-8.3%
0.00%0.0%
Q1 2016$2,608,000
-53.0%
690,128
+94.9%
0.00%0.0%
Q4 2015$5,553,000
+67.2%
354,079
+12.4%
0.00%0.0%
Q3 2015$3,321,000
-53.5%
315,099
+11.4%
0.00%
-50.0%
Q2 2015$7,135,000
-28.0%
282,898
-20.4%
0.00%0.0%
Q1 2015$9,906,000
+32.9%
355,457
-13.0%
0.00%0.0%
Q4 2014$7,454,000
+17.2%
408,483
-16.8%
0.00%0.0%
Q3 2014$6,362,000
-22.2%
490,771
-2.1%
0.00%0.0%
Q2 2014$8,182,000
+166.3%
501,384
+188.4%
0.00%
+100.0%
Q1 2014$3,072,000
-26.3%
173,857
+1.0%
0.00%0.0%
Q4 2013$4,168,000
-60.0%
172,128
-41.5%
0.00%
-66.7%
Q3 2013$10,422,000
+99.5%
294,134
-12.1%
0.00%
+50.0%
Q2 2013$5,225,000334,7400.00%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q4 2014
NameSharesValueWeighting ↓
Ridgeback Capital Investments L.P. 1,025,000$24,815,00031.36%
TSP Capital Management Group, LLC 836,342$20,248,0008.80%
Iguana Healthcare Management, LLC 200,000$4,842,0002.76%
First Light Asset Management, LLC 116,096$2,811,0002.38%
SECTORAL ASSET MANAGEMENT INC 2,227,688$53,932,0002.33%
BENNETT LAWRENCE MANAGEMENT L L C/NY 550,735$13,334,0002.05%
Eventide Asset Management 257,000$6,222,0001.92%
Redmile Group, LLC 397,951$9,634,0001.19%
ARDSLEY ADVISORY PARTNERS LP 357,000$8,643,0001.15%
Rhenman & Partners Asset Management AB 90,000$2,179,0000.85%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders